What is Xeris Biopharma Holdings, Inc.'s return on equity?

Xeris Biopharma Holdings, Inc. (XERS) reported return on equity of -209.8% in Q3 2023.

What is the long-term trend for Xeris Biopharma Holdings, Inc.'s return on equity?

Over 2 years (2020 to 2022), Xeris Biopharma Holdings, Inc.'s return on equity has grown at a -40.3% compound annual growth rate (CAGR), from -378.2% to -134.8%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

Xeris Biopharma Holdings, Inc. XERS Return on equity

Return on equity at other companies

Eli LillyLLY

107.6%+29.9pp

Corcept TherapeuticsCORT

7.2%-14.6pp

Eton Pharmaceuticals, Inc.ETON

-34.2%+0.9pp

Ultragenyx PharmaceuticalRARE

-325.6%+36.9pp

Zevra Therapeutics, Inc.ZVRA

100.7%+60.3pp

ANI PharmaceuticalsANIP

18.8%+15.6pp

Other financials

Income statement

See full

Revenue$83.1M+38.3%

Gross profit$72.6M+41.2%

Operating income$7.9M+356%

Net income$2.2M+124%

EPS (diluted)$0.01+117%

Balance sheet

See full

Cash & equivalents$111.8M+91.2%

Total debt$258.6M-3.8%

Total equity$13.0M+137%

Total assets$392.0M+24.3%

Cash flow

See full

Operating cash flow$9.9M+198%

CapEx$131.0K—

Free cash flow-$29.1M—

Valuation

See full

Market cap$1.28B+18.3%

Enterprise value$1.42B+8.7%

P/E106.4×—

P/S4.1×-0.8×

Profitability

See full

Gross margin85.9%+3.7pp

Operating margin11.4%+7.7pp

Net margin3.8%+2.1pp

Returns & leverage

See full

Debt / equity19.9×—

Current ratio2.1×+0.4×

Where this comes from

Calculated from Xeris Biopharma Holdings, Inc.’s reported figures.

net income/total stockholders equity=-209.8%

Based on trailing twelve months.

The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed November 8, 2024, on SEC EDGAR. View the filing →

Ask your AI about Xeris Biopharma Holdings, Inc.'s return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Xeris Biopharma Holdings, Inc.'s return on equity?: Xeris Biopharma Holdings, Inc. (XERS) reported return on equity of -209.8% in Q3 2023.
What is the long-term trend for Xeris Biopharma Holdings, Inc.'s return on equity?: Over 2 years (2020 to 2022), Xeris Biopharma Holdings, Inc.'s return on equity has grown at a -40.3% compound annual growth rate (CAGR), from -378.2% to -134.8%.
What does return on equity mean?: Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.